Analysis index

1 ml citrate plasma (1+9), cooled down (2°C – 8°C). Do not freeze! Blood taking at peak concentration: 2 – 4 hours after subcutaneous heparin injection. Blood taking at baseline concentration: Before next dose. Please state active substance or trade name of the heparin preparation (please also state HMW (high molecular weight) or LMW (low molecular weight)).

LMW heparin, Fondaparinux:

Thrombosis prophylaxis: 0,2 – 0,4 IU/ml

Thrombosis therapy: 0,4 – 0,8 IU/ml

Orgaran:

Thrombosis prophylaxis: 0,15 – 0,35 IU/ml

Thrombosis therapy: 0,5 – 0,8 IU/ml

Therapy checks of treatment with low molecular heparin (Fragmin®, Clexane®, Fraxiparin®, Fondaparinux (Arixtra®)) and with the heparinoid Orgaran® (Danaparoid) during pregnancy, in case of kidney insufficiency, newborns, suspicion of overdose, long term treatment and high risk of bleeding or thrombosis.

Anti-FXa-checks are generally not required in case of therapy with LMW heparin (exceptions as above). During pregnancy, heparin requirements increase continuously. Thrombocytes should be monitored under LMW heparin therapy (please also refer to section “Heparin-induced platelet activation assay, HIPA”). For checks of the heparin-baseline value, it is required to take a blood sample directly before subcutaneous injection, for checks of the peak concentration value 2 – 4 hours after injection. Avoid taking blood from heparinized lines.

Labor Zentrum Weser Prof. Dr. med. Schmitz Minden